97 related articles for article (PubMed ID: 2502686)
1. Steroid sulfates in testis tissue of prostatic cancer patients treated for six months with the gonadotropin releasing hormone agonist buserelin.
Huhtaniemi I; Rannikko S; Orava M; Vihko R
J Steroid Biochem; 1989 Jun; 32(6):811-3. PubMed ID: 2502686
[TBL] [Abstract][Full Text] [Related]
2. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
[TBL] [Abstract][Full Text] [Related]
3. Lack of a direct effect of gonadotropin hormone-releasing hormone agonist on human testicular steroidogenesis.
Rajfer J; Sikka SC; Swerdloff RS
J Clin Endocrinol Metab; 1987 Jan; 64(1):62-7. PubMed ID: 3023429
[TBL] [Abstract][Full Text] [Related]
4. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
Huhtaniemi I; Nikula H; Rannikko S
J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
[TBL] [Abstract][Full Text] [Related]
5. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Huhtaniemi I; Nikula H; Rannikko S; Clayton R
J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
[TBL] [Abstract][Full Text] [Related]
6. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
7. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
[TBL] [Abstract][Full Text] [Related]
8. Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men.
Schaison G; Brailly S; Vuagnat P; Bouchard P; Milgrom E
J Clin Endocrinol Metab; 1984 May; 58(5):885-8. PubMed ID: 6423662
[TBL] [Abstract][Full Text] [Related]
9. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
Kuber W; Viehberger G; Zeillinger R; Spona J
Urol Res; 1991; 19(1):19-24. PubMed ID: 1827557
[TBL] [Abstract][Full Text] [Related]
10. Studies of the human testis. XVIII. Simultaneous measurement of nine intratesticular steroids: evidence for reduced mitochondrial function in testis of elderly men.
Takahashi J; Higashi Y; LaNasa JA; Yoshida K; Winters SJ; Oshima H; Troen P
J Clin Endocrinol Metab; 1983 Jun; 56(6):1178-87. PubMed ID: 6404920
[TBL] [Abstract][Full Text] [Related]
11. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
12. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the inhibitory effect of chronic treatment with an LHRH agonist on testicular steroidogenesis in the dog.
Tremblay Y; Bélanger A; Labrie F; Frenette G; Dubé JY; Tremblay RR
Prostate; 1984; 5(6):631-8. PubMed ID: 6208541
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
[TBL] [Abstract][Full Text] [Related]
15. The effects of a gonadotropin-releasing hormone agonist on testicular histology.
Waxman J; Lowe D; Whitfield HN; Hendry BF; Besser GM
Fertil Steril; 1987 Dec; 48(6):1067-9. PubMed ID: 3119372
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the direct action of gonadotropin-releasing hormone and its antagonist on androgen biosynthesis by cultured rat testicular cells.
Hsueh AJ; Bambino TH; Zhuang LZ; Welsh TH; Ling NC
Endocrinology; 1983 May; 112(5):1653-61. PubMed ID: 6299703
[TBL] [Abstract][Full Text] [Related]
17. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
[TBL] [Abstract][Full Text] [Related]
18. The effect of early postnatal treatment with a gonadotropin-releasing hormone agonist on the developmental profiles of testicular steroid hormones in the intact male pig.
Sinclair PA; Squires EJ; Raeside JI; Britt JH; Hedgpeth VG
J Anim Sci; 2001 Apr; 79(4):1003-10. PubMed ID: 11325174
[TBL] [Abstract][Full Text] [Related]
19. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
[TBL] [Abstract][Full Text] [Related]
20. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
